Critical Review: Tetralogic Pharmaceuticals (TLOG) versus Mateon Therapeutics (MATN)

Tetralogic Pharmaceuticals (OTCMKTS: TLOG) and Mateon Therapeutics (OTCMKTS:MATN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Tetralogic Pharmaceuticals and Mateon Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tetralogic Pharmaceuticals 0 0 0 0 N/A
Mateon Therapeutics 0 1 3 0 2.75

Mateon Therapeutics has a consensus price target of $1.75, suggesting a potential upside of 766.34%. Given Mateon Therapeutics’ higher possible upside, analysts plainly believe Mateon Therapeutics is more favorable than Tetralogic Pharmaceuticals.

Valuation and Earnings

This table compares Tetralogic Pharmaceuticals and Mateon Therapeutics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Tetralogic Pharmaceuticals N/A N/A -$49.72 million N/A N/A
Mateon Therapeutics N/A N/A -$13.65 million ($0.56) -0.36

Insider & Institutional Ownership

0.0% of Tetralogic Pharmaceuticals shares are held by institutional investors. 15.4% of Tetralogic Pharmaceuticals shares are held by insiders. Comparatively, 4.5% of Mateon Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

Tetralogic Pharmaceuticals has a beta of 2.8, indicating that its share price is 180% more volatile than the S&P 500. Comparatively, Mateon Therapeutics has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500.

Profitability

This table compares Tetralogic Pharmaceuticals and Mateon Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Tetralogic Pharmaceuticals N/A N/A N/A
Mateon Therapeutics N/A -210.82% -175.67%

Summary

Tetralogic Pharmaceuticals beats Mateon Therapeutics on 5 of the 8 factors compared between the two stocks.

Tetralogic Pharmaceuticals Company Profile

TetraLogic Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics in oncology, infectious diseases and autoimmune diseases. The Company’s segment is the identification and development of novel small molecule therapies in oncology and infectious diseases. The Company has approximately two clinical-stage product candidates in development, such as birinapant and SHAPE. SHAPE is the Company’s histone deacetylase (HDAC) inhibitor that it is developing for topical use for the treatment of early-stage cutaneous T-cell lymphoma (CTCL). The Company is also exploring studying SHAPE in alopecia areata, an autoimmune skin disease. SHAPE has been granted the United States orphan drug designation for CTCL. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases (SMAC)-mimetic, which leads to apoptosis or cell-death in damaged cells.

Mateon Therapeutics Company Profile

Mateon Therapeutics, Inc., formerly OXiGENE, Inc., is a biopharmaceutical company. The Company is focused on the development of vascular disrupting agents (VDAs) for the treatment of cancer. The Company is engaged in developing two clinical stage investigational drugs: VDAs-CA4P and OXi4503. Its lead compound is CA4P, which is also known as combretastatin A4-phosphate, fosbretabulin tromethamine, fosbretabulin and ZYBRESTAT. VDAs selectively targets the vasculature of cancer tumors and obstructs a tumor’s blood supply without disrupting the blood supply to normal tissues. VDAs are in a class of drugs called vascular targeted therapies (VTTs), which also includes anti-angiogenic agents (AAs). CA4P is a reversible tubulin binding agent that selectively targets the endothelial cells that make up the blood vessel walls in solid tumors. The Company is pursuing the development of a product candidate, OXi4503, which is a dual-mechanism VDA.

Receive News & Ratings for Tetralogic Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetralogic Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit